478 related articles for article (PubMed ID: 12382158)
1. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
2. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
4. Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study.
Parisi R; Visonà A; Camporese G; Verlato F; Lessiani G; Antignani PL; Palareti G
Int Angiol; 2009 Feb; 28(1):68-72. PubMed ID: 19190559
[TBL] [Abstract][Full Text] [Related]
5. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
6. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
Labas P; Ohrádka B; Vladimír J; Cambal M
Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
9. [Protocol for ambulant treatment of deep venous thrombosis in a leg: efficacious and safe in general practice].
van Hulsteijn LH; Brenninkmeijer BJ; Trügg RA; Litjens-van de Ven AJ; Huisman MV
Ned Tijdschr Geneeskd; 2000 Mar; 144(12):557-60. PubMed ID: 10746047
[TBL] [Abstract][Full Text] [Related]
10. [Prophylaxis for deep vein thrombosis with low molecular weight heparin following hip and knee surgery].
Li XL; Lu WJ; Yu NS
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2001 Jan; 15(1):39-41. PubMed ID: 12563929
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.
Adolf J; Fritsche HM; Haas S; Hennig FF; Horbach T; Kastl S; Koppenhagen K; Michaelis HC; Rhamanzadeh R; Summa W; Wagner W; Weber U; Wolf H
Int Angiol; 1999 Jun; 18(2):122-6. PubMed ID: 10424367
[TBL] [Abstract][Full Text] [Related]
12. Home treatment of deep vein thrombosis: a two-years experience of a single institution.
Grau E; Real E; Pastor E; Viciano V; Aguiló J
Haematologica; 1998 May; 83(5):438-41. PubMed ID: 9658729
[TBL] [Abstract][Full Text] [Related]
13. Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Ennis RS
J South Orthop Assoc; 2003; 12(1):10-7. PubMed ID: 12735619
[TBL] [Abstract][Full Text] [Related]
14. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
Blatný J; Fiamoli V
Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11).
Moreno Gonzalez E; Fontcuberta J; de la Llama F
Hepatogastroenterology; 1996; 43(9):744-7. PubMed ID: 8799424
[TBL] [Abstract][Full Text] [Related]
16. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
17. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
[TBL] [Abstract][Full Text] [Related]
18. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis].
Moreno-Palomares JJ; Fisac-Herrero RM; Herrero-Domingo A; Ferreira-Pasos EM; Grasa J; Reverte-Cejudo D
An Med Interna; 2001 Jul; 18(7):364-8. PubMed ID: 11534421
[TBL] [Abstract][Full Text] [Related]
19. [The insufficiency of low molecular weight heparin (LMWH) prophylaxis in patients with hereditary antithrombin (AT) deficiency].
Dybowska M; Kuca P; Gralec R; Burakowski J; Tomkowski WZ
Pneumonol Alergol Pol; 2007; 75(3):278-82. PubMed ID: 17966105
[TBL] [Abstract][Full Text] [Related]
20. The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin.
Partsch H; Kechavarz B; Köhn H; Mostbeck A
Int Angiol; 1997 Sep; 16(3):189-92. PubMed ID: 9405014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
